Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05656131

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer，A Two-cohort, Open, Multicenter，Phase II Study

Sponsor: wang shusen

Conditions Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Interventions Fluzoparib Fluzoparib+Camrelizumab

Updated 4 times since 2023 Last updated: Jan 27, 2023 Started: Nov 23, 2022 Primary completion: Mar 30, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer and is currently actively recruiting participants. wang shusen leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Feb 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE2

First recorded

Nov 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

wang shusen

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China